Zacks: Brokerages Expect Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) to Announce -$1.68 Earnings Per Share
Analysts expect Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) to report earnings per share of ($1.68) for the current fiscal quarter, Zacks reports. Eight analysts have provided estimates for Ultragenyx Pharmaceutical’s earnings. The highest EPS estimate is ($1.49) and the lowest is ($1.97). Ultragenyx Pharmaceutical reported earnings of ($1.74) per share in the same quarter last year, which would indicate a positive year over year growth rate of 3.4%. The business is expected to announce its next earnings results on Monday, November 4th.
According to Zacks, analysts expect that Ultragenyx Pharmaceutical will report full year earnings of ($6.72) per share for the current financial year, with EPS estimates ranging from ($7.42) to ($6.47). For the next financial year, analysts forecast that the firm will report earnings of ($5.21) per share, with EPS estimates ranging from ($7.36) to ($2.34). Zacks’ earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for Ultragenyx Pharmaceutical.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.72) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.73) by $0.01. Ultragenyx Pharmaceutical had a negative return on equity of 49.84% and a negative net margin of 527.49%. The company had revenue of $24.15 million for the quarter, compared to analyst estimates of $22.16 million. During the same period in the prior year, the company posted ($1.06) EPS. The firm’s quarterly revenue was up 88.8% compared to the same quarter last year.
In related news, EVP Karah Herdman Parschauer sold 1,226 shares of the firm’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $61.50, for a total transaction of $75,399.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Emil D. Kakkis bought 5,000 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Wednesday, September 11th. The shares were acquired at an average cost of $43.63 per share, with a total value of $218,150.00. Following the acquisition, the chief executive officer now owns 472,479 shares of the company’s stock, valued at $20,614,258.77. The disclosure for this purchase can be found here. Insiders own 7.80% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of RARE. First Mercantile Trust Co. raised its stake in shares of Ultragenyx Pharmaceutical by 16.9% during the 2nd quarter. First Mercantile Trust Co. now owns 1,151 shares of the biopharmaceutical company’s stock valued at $73,000 after buying an additional 166 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Ultragenyx Pharmaceutical by 6.8% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,325 shares of the biopharmaceutical company’s stock worth $211,000 after acquiring an additional 212 shares during the period. United Services Automobile Association grew its holdings in Ultragenyx Pharmaceutical by 0.7% during the second quarter. United Services Automobile Association now owns 31,483 shares of the biopharmaceutical company’s stock worth $1,999,000 after acquiring an additional 215 shares during the period. Smith Asset Management Group LP raised its position in Ultragenyx Pharmaceutical by 22.6% during the second quarter. Smith Asset Management Group LP now owns 1,680 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 310 shares in the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in Ultragenyx Pharmaceutical by 19.7% during the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 2,303 shares of the biopharmaceutical company’s stock valued at $160,000 after acquiring an additional 379 shares in the last quarter.
NASDAQ RARE traded up $1.88 during trading on Friday, hitting $45.01. The company’s stock had a trading volume of 1,933,591 shares, compared to its average volume of 542,595. Ultragenyx Pharmaceutical has a fifty-two week low of $37.44 and a fifty-two week high of $90.98. The company has a market cap of $2.60 billion, a PE ratio of -6.09 and a beta of 2.13. The company has a debt-to-equity ratio of 0.04, a current ratio of 9.32 and a quick ratio of 9.14. The business’s 50 day simple moving average is $55.85 and its 200-day simple moving average is $61.69.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.
Read More: How to Invest in a Bull Market
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.